- Home
- LQDA
LQDA
Liquidia Corporation
as 06-20-2025 4:00pm EST
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | MORRISVILLE |
| Market Cap: | 1.3B | IPO Year: | 2018 |
| Target Price: | $27.67 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.71 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.26 - $19.41 | Next Earning Date: | 08-06-2025 |
| Revenue: | $14,144,000 | Revenue Growth: | -11.42% |
| Revenue Growth (this year): | 185.38% | Revenue Growth (next year): | 350.95% |
Stock Insider Trading Activity of Liquidia Corporation (LQDA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Moomaw Scott | LQDA | Chief Commercial Officer | Jun 3 '25 | Sell | $16.97 | 6,656 | $112,952.32 | 224,921 | |
| JEFFS ROGER | LQDA | Chief Executive Officer | Jun 3 '25 | Sell | $16.97 | 30,610 | $519,451.70 | 1,044,979 | |
| Kaseta Michael | LQDA | CFO and COO | Jun 3 '25 | Sell | $16.97 | 14,777 | $250,765.69 | 412,164 | |
| Saggar Rajeev | LQDA | Chief Medical Officer | Jun 3 '25 | Sell | $16.97 | 7,597 | $128,921.09 | 273,209 | |
| Adair Jason | LQDA | Chief Business Officer | Jun 3 '25 | Sell | $16.97 | 3,597 | $61,041.09 | 193,735 | |
| Schundler Russell | LQDA | General Counsel | Jun 3 '25 | Sell | $16.97 | 8,460 | $143,566.20 | 582,054 | |
| Moomaw Scott | LQDA | Chief Commercial Officer | May 30 '25 | Sell | $16.74 | 581 | $9,725.94 | 224,921 | |
| Kaseta Michael | LQDA | CFO and COO | May 30 '25 | Sell | $16.74 | 859 | $14,379.66 | 412,164 | |
| Adair Jason | LQDA | Chief Business Officer | May 30 '25 | Sell | $16.74 | 451 | $7,549.74 | 193,735 | |
| Schundler Russell | LQDA | General Counsel | May 30 '25 | Sell | $16.74 | 923 | $15,451.02 | 582,054 |
Latest Liquidia Corporation News
LQDA Breaking Stock News: Dive into LQDA Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Top Growth Companies With Insider Stakes In June 2025
Investor's Business Daily
10 days ago
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia
MT Newswires
19 days ago
Liquidia Set to Make First Commercial Shipment of Yutrepia for Pulmonary Hypertension
GlobeNewswire
19 days ago
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
GlobeNewswire
24 days ago
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference
MT Newswires
25 days ago
Jefferies Lifts Liquidia Technologies' Price Target to $31 From $27, Buy Rating Kept
Insider Monkey
a month ago
FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute
MT Newswires
a month ago
Liquidia Receives FDA Approval on Yutrepia for Treatment of Pulmonary Hypertension
Compare LQDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LQDA Liquidia Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.